Hepatitis C Virus Nucleotide Inhibitors PSI-352938 and PSI-353661 Exhibit a Novel Mechanism of Resistance Requiring Multiple Mutations within Replicon RNA
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hepatitis C Virus Nucleotide Inhibitors PSI-352938 and PSI-353661 Exhibit a Novel Mechanism of Resistance Requiring Multiple Mutations within Replicon RNA
Authors
Keywords
-
Journal
JOURNAL OF VIROLOGY
Volume 85, Issue 23, Pages 12334-12342
Publisher
American Society for Microbiology
Online
2011-09-29
DOI
10.1128/jvi.05639-11
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibition of Hepatitis C Virus Replicon RNA Synthesis by PSI-352938, a Cyclic Phosphate Prodrug of β-d-2′-Deoxy-2′-α-Fluoro-2′-β-C-Methylguanosine
- (2011) Angela M. Lam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- INX-08189, a Phosphoramidate Prodrug of 6-O-Methyl-2′-C-Methyl Guanosine, Is a Potent Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic and Pharmacodynamic Properties
- (2011) John H. Vernachio et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661
- (2011) Phillip A. Furman et al. ANTIVIRAL RESEARCH
- 1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS
- (2011) A. Lok et al. JOURNAL OF HEPATOLOGY
- 1372 ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY
- (2011) D.R. Nelson et al. JOURNAL OF HEPATOLOGY
- A Comprehensive Structure-Function Comparison of Hepatitis C Virus Strain JFH1 and J6 Polymerases Reveals a Key Residue Stimulating Replication in Cell Culture across Genotypes
- (2011) M. Schmitt et al. JOURNAL OF VIROLOGY
- RG7128 Alone or in Combination with Pegylated Interferon‐α2a and Ribavirin Prevents Hepatitis C Virus (HCV) Replication and Selection of Resistant Variants in HCV‐Infected Patients
- (2010) Sophie Le Pogam et al. JOURNAL OF INFECTIOUS DISEASES
- Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus
- (2010) Michael J. Sofia et al. JOURNAL OF MEDICINAL CHEMISTRY
- Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
- (2009) Christoph Sarrazin et al. GASTROENTEROLOGY
- Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)
- (2009) T. L. Kieffer et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antiviral resistance and specifically targeted therapy for HCV (STAT-C)
- (2009) A. J. V. Thompson et al. JOURNAL OF VIRAL HEPATITIS
- Structural and Functional Analysis of Hepatitis C Virus Strain JFH1 Polymerase
- (2009) P. Simister et al. JOURNAL OF VIROLOGY
- Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479
- (2008) S. Ali et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors
- (2008) M. F. McCown et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Resistance mechanisms in HCV: from evolution to intervention
- (2008) Arthur Y Kim et al. Expert Review of Anti-Infective Therapy
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
- (2008) Thomas Kuntzen et al. HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More